Skip to content
‹ Back to IndustriesHealthcare

J&J Vaccine Highlights the Desire for Simplicity and Speed in Healthcare

Johnson & Johnson’s Covid-19 vaccine is safe and 72% effective in a U.S. clinical trial, Food and Drug Administration staff said. Watch above or read part of the interview below for Bloomberg Intelligence’s Sam Fazeli thoughts on the simplicity and efficiency implications of the Johnson & Johnson Covid-19 vaccine. — Host: Sam, in the heart…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share
J&J Vaccine Highlights the Desire for Simplicity and Speed in Healthcare

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Johnson & Johnson’s Covid-19 vaccine is safe and 72% effective in a U.S. clinical trial, Food and Drug Administration staff said. Watch above or read part of the interview below for Bloomberg Intelligence’s Sam Fazeli thoughts on the simplicity and efficiency implications of the Johnson & Johnson Covid-19 vaccine.

—

Host: Sam, in the heart of the matter, this is a search for simplicity. Peter Hotez of Baylor makes it very clear what we need globally is a simplicity of vaccine delivery. Does J&J accomplish that?

Fazeli: So I don’t think you can get simpler than the J&J vaccine. It needs very basic refrigeration and it’s one dose. So absolutely.

Host: When could we actually see it getting rolled out in the United states?

Fazeli: I think the dates that I’ve been hearing is in the next month or two, they did have some manufacturing issues, but certainly picking up rapidly going into the second half. So but let’s not forget that this vaccine, you know, the US has enough Moderna and Pfizer vaccines now to cover the entirety of the population, at least ordered. So this is a vaccine that really could make a difference to the rest of the world.

Host: Let me ask you the question that I’ve asked all of our esteemed guests in virology, which is from where you sit, Sam, do you look at the better statistics as an extrapolation forward into the spring of this year? Can you extrapolate to an optimistic outcome?

Fazeli: Tom, as you know, I would love to because it’s also my life. But but I am always wary of these variants that are circling. And I would love to think that they are not going to make a difference. And if you look at some countries where they have the B117 variant that was first identified in the UK, they’ve managed to get it under control with lockdown measures. So if we are careful, we can keep it under control. If we’re not. And we go into big gatherings, et cetera. I think there’s a risk that we might have another wave.

*Bloomberg contributed to this article

—

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Avanlee Care’s $3.5M seed tests whether Medicare Advantage plans will pay to reach caregivers

Avanlee Care’s $3.5M seed tests whether Medicare Advantage plans will pay to reach caregivers

Avanlee Care raised a $3.5 million seed round led by BEA Venture Fund, bringing total funding to $6 million. The startup helps Medicare Advantage plans find and support members' family caregivers. Its bet: plans will pay to reach whoever books the visits.

  • 01Medicare Advantage plans can see overdue visits and refills; Avanlee Care’s $3.5M seed backs a per-member-per-month model to reach the family caregiver who can act on that outreach.
  • 02Caregiver support among Medicare Advantage Special Needs Plans rose from 5% of plans in 2025 to 16% in 2026, even as meals and transportation benefits declined. That gives benefit designers a reference point.

Nov 15, 2026

Oura's $625 million Counsel Health deal puts a ring maker in the triage business

Oura's $625 million Counsel Health deal puts a ring maker in the triage business

Oura is buying Counsel Health for $625 million in cash, bringing an AI chat service with on-demand physicians in-house. Counsel will keep selling triage and virtual care to health plans, health systems and employers. Outcomes data is still to come.

  • 01For $625 million in cash, a smart ring company now owns a service pitched to health plans as a replacement for the nurse triage line.
  • 02Counsel's website offers a free conversation with Counsel AI and lets users add a doctor for $29, a public reference point benefits teams could use when comparing virtual care costs.
  • 03The evidence behind the combined model is member satisfaction (4.6 out of 5) and self-reported surveys; clinical outcomes and cost results are the numbers that would confirm it.

Nov 15, 2026

Ohio State–Microsoft deal, reported at $250M, targets 70–80% of storage/compute to Azure

Ohio State–Microsoft deal, reported at $250M, targets 70–80% of storage/compute to Azure

Ohio State University and Microsoft’s five-year partnership, reported by outlets at $250 million, is largely infrastructure: targeting a shift of roughly 70% to 80% of storage and computing to Azure and building a shared data layer. Note-drafting AI already runs. Smart-room features for patients come later and depend on that foundation.

  • 01The only part of the Ohio State and Microsoft deal with published results is AI note drafting, which saved up to four minutes per visit in Wexner's 2024 pilot.
  • 02Smart-room capabilities (such as personalized lighting) depend on a shared data layer whose high-level design is complete; early measurable returns may show up first in OR and staffing forecasts.
  • 03Health systems weighing a similar platform deal should ask how the headline value breaks down, which workloads move first and whether the cloud copy of the EHR is a backup or the primary record.

Nov 14, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512